RS Research

RS Research is a clinical-stage biotechnology start-up developing novel nanomedicines. We have discovered a novel drug delivery platform with which we currently have development programs in various preclinical and clinical stages for therapies to treat patients fighting cancer. Our nanocarrier platform (Sagitta®) is highly tunable with a plug & play approach, allowing rapid development of targeted nanomedicines with superior performance aiming multiple indications. Along with moving our own candidates toward clinic, we provide preclinical services to industrial and academic partners. We have specific expertise in biosimilar characterization as well as in vivo experiment design and implementation. Our GMP certified production facility is the first cytotoxic-capable clinical batch-size contract organization for such services in the region.

RS Research headquartered in Europe, operates in the Biotechnology, Pharmaceutical sector. The company focuses on Biotechnology and has secured $342.1M in funding across 24 round(s). With a team of 101-250 employees, RS Research is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - RS Research, raised $1.2M. Discover more about their projects, partnerships, and impact on our platform.